AI English summary of an SEC filing — figures as filed

Danaher said net earnings from continuing operations for Q2 2024 (ended June 28, 2024) were $907 million ($1.22 per diluted share), and revenue fell 3.0% year over year to $5.7 billion. Adjusted diluted net earnings per share (non-GAAP) were $1.72.

8-KResults of Operations and Financial ConditionFiled Jul 23, 2024Period of report Jul 23, 2024Summary published (UTC) Oct 20, 2026

Key points

AI summary

Danaher said net earnings from continuing operations for Q2 2024 (ended June 28, 2024) were $907 million ($1.22 per diluted share), and revenue fell 3.0% year over year to $5.7 billion. Adjusted diluted net earnings per share (non-GAAP) were $1.72.
The company said non-GAAP core revenue fell 3.5% in Q2. By segment, Biotechnology fell 7.0%, Life Sciences fell 5.5%, and Diagnostics rose 3.0%.
Danaher reported operating cash flow from continuing operations of $1,417 million and non-GAAP free cash flow of $1,131 million for Q2. The comparable prior-year figures were $1,646 million and $1,319 million, respectively.
The company said it expects non-GAAP core revenue for Q3 2024 to decline low-single digits year over year. It also said it continues to expect full-year core revenue to decline low-single digits.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Q2 Results: Revenue $5.7 billion, Net Earnings $907 million

Danaher said net earnings from continuing operations for Q2 2024 (ended June 28, 2024) were $907 million ($1.22 per diluted share), and revenue fell 3.0% year over year to $5.7 billion. Adjusted diluted net earnings per share (non-GAAP) were $1.72.

Source · Based on the filing body and exhibits

Q2 Core Revenue Down 3.5%, Segments Diverge

The company said non-GAAP core revenue fell 3.5% in Q2. By segment, Biotechnology fell 7.0%, Life Sciences fell 5.5%, and Diagnostics rose 3.0%.

Source · Based on the filing body and exhibits

Q2 Operating Cash Flow and Free Cash Flow

Danaher reported operating cash flow from continuing operations of $1,417 million and non-GAAP free cash flow of $1,131 million for Q2. The comparable prior-year figures were $1,646 million and $1,319 million, respectively.

Source · Based on the filing body and exhibits

Q3 Results and Full-Year Core Revenue Outlook

The company said it expects non-GAAP core revenue for Q3 2024 to decline low-single digits year over year. It also said it continues to expect full-year core revenue to decline low-single digits.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.